Evidence map›Paper›PMID 41256686›Full record

ArticlebioRxiv : the preprint server for biology2025

Synthetic signaling platform uncovers and rewires cellular responses to PD-1 perturbation.

Zhixing Ma, Lars Hellweg, Susanna K Elledge, Jasper B Lee, Maria Caterina Rotiroti, Kai W Wucherpfennig, Robbie G Majzner, Xin Zhou

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhixing MaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Lars HellwegDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Susanna K ElledgeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jasper B LeeDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston 02115, MA, USA.
Maria Caterina RotirotiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston 02115, MA, USA.
Robbie G MajznerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Xin ZhouDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Funding

Engineering programmable enzymes for proteome editingDP2GM154013 · NIGMS · DANA-FARBER CANCER INST · PI Xin Zhou · 2023 to 2026
$2.7M
Hijacking the T cell machinery for logic-gated CAR T cell controlDP2CA272092 · NCI · STANFORD UNIVERSITY · PI MAJZNER, ROBBIE G. · 2021 to 2024
$2.5M
Interrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domainsR00EB030587 · NIBIB · DANA-FARBER CANCER INST · PI ZHOU, XIN · 2022 to 2024
$733k
NCI NIH HHS DP2 CA272092NIBIB NIH HHS R00 EB030587NIGMS NIH HHS DP2 GM154013
6 · The paper itself

Abstract

Tyrosine phosphorylation motifs are central regulators of cell signaling, yet methods to selectively detect and reprogram these events have been lacking. Here we introduce Sphyder (Selective PHosphotYrosine DEtection and Rewiring), which enables precise detection of signaling at the resolution of individual phosphorylation motifs. Using Sphyder biosensors, we resolved phosphorylation dynamics and uncovered regulatory mechanisms of the checkpoint receptor PD-1 in living cells. Sphyder also provided a framework for reconstructing phosphosignaling pathways. With this approach, we redirected PD-1 signaling from immunosuppressive to immunoactivating outputs and engineered synthetic receptors that linked extracellular sensing to customized transcriptional programs. In addition, Sphyder biosensors revealed previously unrecognized mechanisms of the PD-1/VEGF bispecific antibody Ivonescimab, showing that it induces VEGF-dependent clustering, phosphorylation, and degradation of PD-1. These findings may underlie its promising clinical activity relative to conventional PD-1 blockade. Together, our study establishes a broadly applicable strategy for sensing and reprogramming cell signaling, while also providing mechanistic insights into a new class of immune checkpoint inhibitors of major clinical interest.

Identifiers

PMID41256686
PMCPMC12621876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.